Anti-Human Transmembrane Activator & CAML Interactor (TACI)

Purified Recombinant Human TACI (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

Lyophilized

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Immunohistochemistry: Suitable for use at concentration of 5-15 µg/mL.
Blocking: In a functional ELISA, 0.075-0.3 µg/mL of this antibody will block 50% of the binding of 50 ng/mL of Recombinant Human BAFF/BLyS/TNFSF13B o immobilized Recombinant Human TACI/TNFRSF13B Fc Chimera coated at 1 µg/mL (100 µL/well). At 10 μg/mL, this antibody will block >90% of the binding.

Goat Anti-Human Transmembrane Activator & CAML Interactor (TACI) recognizes Human TACI. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Transmembrane activator & calcium modulator and cyclophilin ligand (CAML) interactor (TACI) is lymphocyte specific member^1,2 of the tumor necrosis factor-receptor superfamily³ and is expressed in B-lymphocytes and may act to regulate humoral immunity.⁴ TACI also serves as a receptor for B-cell activating factor of the TNF family (BAFF) and as a proliferation-inducing ligand (APRIL).⁵

1. Schwaller, J. et al. (2007) Blood 109:331
2. Slazer, U. et al. (2005) Nat Genet. 37:820
3. Bonilla, FA. et al. (2006) Curr Allergy Asthma Rep. 6:357
4. Bram, RJ. et al. (2000) Mamm Genome. 11:628
5. Kobata, T. et al. (2007) Blood 109: 2961